Advanced AI molecular representations and generative models promise to speed drug discovery by predicting PD and toxicity earlier and enabling de novo design; but most demonstrated gains are in silico or preclinical and depend critically on data quality, 3D fidelity and still-maturing quantum approaches.

Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications

Xiaoyu Zhou, Weijing Tao · Fetched April 20, 2026 · Frontiers in Bioinformatics

semantic_scholar review_meta n/a evidence 7/10 relevance DOI Source

The review argues that advanced molecular representations and AI methods — from GNNs and 3D-aware geometric learning to emerging quantum approaches — can accelerate drug discovery by enabling earlier prediction of pharmacodynamic and toxicological properties and by powering generative design and data-efficient learning.

The pharmaceutical research and development (R&D) process is persistently challenged by high financial costs, protracted timelines, and remarkably low success rates. Artificial intelligence (AI) technology, by simulating complex biological systems, has accelerated the innovation of the entire drug discovery pipeline. This review positions AI as a pivotal technology for reengineering the R&D process by utilizing sophisticated molecular representations to predict pharmacodynamic (PD) and toxicological effects significantly earlier. The scope systematically covers the AI foundations in chemoinformatics, detailing how the performance of AI models is intrinsically linked to the quality of molecular representation. We elaborate on representations ranging from robust string-based methods to advanced topological models, including the five key categories of Graph Neural Networks (GNNs), three-dimensional (3D)-aware Geometric Deep Learning (GDL) and emerging Quantum Machine Learning (QML) as well as Hybrid Quantum-Classical Neural Networks (HQNNs). We analyzed the practical application of these models across the drug discovery pipeline, including de novo molecular design with biological foundation models and flow matching generative architectures, data scarcity solutions via Few-Shot Learning and meta-learning, and explainable AI (XAI) for transparent validation. We propose an integrated Q-BioFusion framework that synergizes quantum computing, autonomous experimentation, and generative models to address systemic R&D constraints. We hope future research will improve the geometric fidelity to achieve more accurate and faster 3D molecular prediction and generation, enhance data efficiency, and solve the inherent data sparsity problem in biological assays, and advance integrated XAI workflows. These efforts will ensure transparent, reliable and trustworthy guidance during the computer simulation process of drug design.

Summary

Main Finding

AI—driven by richer molecular representations (from string-based encodings to 3D-aware geometric models and quantum-informed techniques)—can materially reengineer pharmaceutical R&D by predicting pharmacodynamic and toxicological properties earlier in the pipeline, improving de novo design, and addressing data sparsity through few‑shot/meta‑learning and explainable AI. An integrated Q-BioFusion paradigm (quantum computing + autonomous experimentation + generative models) is proposed as a pathway to overcome persistent cost, time, and success‑rate constraints, though gains depend on improvements in 3D geometric fidelity, data efficiency, and trustworthy XAI pipelines.

Key Points

Core thesis: model performance is tightly coupled to the quality of molecular representation; better representations enable earlier and more reliable PD/tox predictions.
Representation spectrum reviewed:
- String-based methods (SMILES, SELFIES) — robust, computationally cheap.
- Graph Neural Networks (GNNs) — five key categories for relational structure learning.
- 3D-aware Geometric Deep Learning (GDL) — captures spatial geometry crucial for binding/toxicity.
- Quantum Machine Learning (QML) and Hybrid Quantum‑Classical Neural Networks (HQNNs) — emerging for handling quantum effects and richer feature spaces.
Practical applications covered:
- De novo molecular design using biological foundation models and flow‑matching generative architectures.
- Data scarcity solutions: few‑shot learning, meta‑learning, transfer learning.
- Explainable AI (XAI) methods for model validation and regulatory transparency.
Proposed Q-BioFusion framework: integrates quantum computing, autonomous lab experimentation (closed‑loop), and generative models to accelerate discovery and validate predictions experimentally.
Outstanding technical needs: higher geometric fidelity in 3D predictions/generation, greater data efficiency to overcome assay sparsity, and integrated XAI workflows for trustworthy decision support.

Data & Methods

Paper type: systematic review and conceptual framework proposal.
Literature synthesis across chemoinformatics, ML model classes, generative model architectures, quantum ML, few‑shot/meta‑learning, and XAI methods.
Comparative/qualitative analysis of model families by representational capacity (1D strings → 2D graphs → 3D geometry → quantum descriptors).
Surveyed practical pipeline use cases: virtual screening, lead optimization, de novo generation, and closed‑loop experimental validation.
Methodological emphasis: mapping capabilities and limitations (data requirements, geometric fidelity, interpretability) rather than introducing new empirical datasets or benchmarks.
Evaluation criteria discussed in the review: prediction accuracy for PD/tox endpoints, generative validity/diversity, sample efficiency (few‑shot behavior), and explainability/traceability for regulatory uptake.

Implications for AI Economics

R&D productivity and cost structure
- Potential to reduce marginal cost per candidate and shorten time-to-hit-to-lead and lead optimization stages by earlier PD/tox filtering.
- Gains materialize as higher effective R&D productivity (more experiment value per dollar), potentially raising portfolio expected returns and lowering required pipeline breadth.
Capital allocation and factor substitution
- Shift of investment toward compute, large curated datasets, simulation infrastructure, and specialized personnel (ML + domain scientists).
- Potential substitution of some wet‑lab screening capacity with in silico evaluation and autonomous experimentation, altering labor demand and capital composition.
Returns to scale and concentration
- Strong data and compute requirements create scale and network effects: firms with larger proprietary datasets and compute budgets may capture outsized advantages, increasing market concentration risks.
- Public datasets, federated learning, and data cooperatives could mitigate concentration but face IP/privacy barriers.
Risk, uncertainty, and regulatory value of XAI
- Explainability and validated predictive performance are economic prerequisites for regulatory acceptance and de‑risking investment in downstream clinical stages.
- XAI investments reduce informational frictions and the cost of capital by improving traceability and auditability of in silico claims.
Quantum and frontier compute economics
- Quantum/Hybrid approaches offer potential long‑run gains but currently entail high capital and operational costs; near‑term economic value depends on proving quantum advantage on relevant molecular tasks.
- Adoption timing uncertain; firms must weigh long R&D lead times for quantum infrastructure against possible step‑changes in capability.
Data scarcity and market mechanisms
- Data sparsity in biological assays constrains model accuracy; economic solutions include data marketplaces, precompetitive consortia, and pricing mechanisms for assay data.
- Few‑shot and meta‑learning reduce dependence on massive labeled datasets, lowering entry barriers for smaller players.
Measuring economic impact
- Recommended metrics: reduction in cost-per-IND candidate, decrease in average time-to-IND, percent increase in success probability at each phase, ROI on compute/data/XAI investments, and changes in required pipeline breadth.
Policy and strategic considerations
- Public funding for benchmark datasets and standards (including XAI/validation protocols) can accelerate diffusion and reduce monopolistic tendencies.
- Regulatory frameworks should adapt to evaluate AI-derived candidates, emphasizing provenance, model validation, and post‑market surveillance to manage residual risk.

Overall, the review suggests meaningful economic upside from integrating advanced molecular representations and AI architectures into drug discovery, but the magnitude and distribution of gains will depend on data access, compute investments, regulatory acceptance, and the pace at which geometric fidelity, data efficiency, and explainability are improved.

Assessment

Paper Typereview_meta Evidence Strengthn/a — This is a literature review synthesizing methodological and application work rather than presenting original causal or empirical identification; it compiles evidence from diverse computational studies and proposals rather than providing new causal estimates. Methods Rigormedium — The paper appears comprehensive in scope—covering chemoinformatics representations, GNNs, 3D geometric models, QML/HQNNs, generative design, few-shot/meta-learning, and XAI—and proposes an integrated framework, but it does not report a clearly described systematic search strategy, inclusion/exclusion criteria, or formal quality/risk-of-bias assessment typical of high-rigor systematic reviews. SampleA narrative/systematic synthesis of published computational and experimental literature on AI for drug discovery, drawing on model-development papers (GNNs, 3D geometric deep learning, quantum ML and hybrid architectures), generative molecule design studies, few-shot/meta-learning and data-efficiency work, explainable AI research, and illustrative preclinical assay results; no original primary dataset is reported. Themesinnovation productivity GeneralizabilityDomain-specific to pharmaceutical R&D; findings may not generalize to other sectors of the economy or to non-molecular applications., Many cited results are in silico or preclinical — limited evidence of downstream clinical or commercial productivity gains., Quantum ML and HQNN sections are forward-looking; practical applicability is constrained by current hardware and scalability limits., Performance claims depend heavily on availability and quality of molecular and assay data; transferability to low-data targets is uncertain despite few-shot proposals., Regulatory, institutional, and cost barriers in drug development could limit real-world adoption and speed-to-market benefits.

Claims (10)

Claim	Direction	Confidence	Outcome	Details
The pharmaceutical R&D process is persistently challenged by high financial costs, protracted timelines, and remarkably low success rates. Organizational Efficiency	negative	high	financial costs, timelines, and success rates of pharmaceutical R&D	0.24
AI technology, by simulating complex biological systems, has accelerated the innovation of the entire drug discovery pipeline. Innovation Output	positive	high	rate of innovation in drug discovery pipeline	0.24
AI can predict pharmacodynamic (PD) and toxicological effects significantly earlier in the drug discovery process. Task Completion Time	positive	high	timing of PD and toxicity prediction	0.24
The performance of AI models in chemoinformatics is intrinsically linked to the quality of molecular representation. Output Quality	positive	high	AI model predictive performance	0.24
Molecular representations discussed include string-based methods, topological models, five key categories of Graph Neural Networks (GNNs), 3D-aware Geometric Deep Learning (GDL), emerging Quantum Machine Learning (QML), and Hybrid Quantum-Classical Neural Networks (HQNNs). Other	null_result	high	categorization of molecular representation methods	0.12
De novo molecular design is being applied using biological foundation models and flow-matching generative architectures. Innovation Output	positive	high	ability to generate novel molecules (de novo design)	0.12
Data scarcity in biological assays can be mitigated via Few-Shot Learning and meta-learning approaches. Other	positive	high	model performance under limited-data conditions / data efficiency	0.12
Explainable AI (XAI) methods support transparent validation and trustworthy guidance during computer simulation in drug design. Ai Safety And Ethics	positive	high	transparency and trustworthiness of simulation-based guidance	0.12
The authors propose an integrated Q-BioFusion framework that synergizes quantum computing, autonomous experimentation, and generative models to address systemic R&D constraints. Organizational Efficiency	positive	high	capacity to address systemic R&D constraints	0.04
Future work improving geometric fidelity, data efficiency, and integrated XAI workflows will lead to more accurate and faster 3D molecular prediction and generation and ensure transparent, reliable guidance in drug design. Ai Safety And Ethics	positive	high	accuracy and speed of 3D molecular prediction/generation and transparency of guidance	0.04